Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of MK-2225 in Healthy Participants
NCT06643390Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACE-1334 in systemic sclerosis (SSc) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) at 20 weeks and Number of Participants Who Discontinue Study Treatment Due to an AE at 8 weeks. Started Nov 2023; status: completed.
02
Drugs
ACE-1334
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06643390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643390.